 "Jubilant Pharma arm to raise $400 mn from Standard Chartered to repay debt")
Jubilant Pharma Holdings on Wednesday said it has signed an agreement with Standard Chartered Bank for a five-year loan of USD 400 million, about Rs 3,186 crore.
Majority of the amount will be used for repayment of existing term loan and debt bonds, the company said in a regulatory filing.
While the term loan and bonds aggregate to USD 350 million, about Rs 2,787 crore, the company is raising another tranche of USD 50 million (about Rs 400 crore) for capital expenditure.
"Jubilant Pharmova Limited's wholly-owned subsidiary Jubilant Pharma Limited today announced that its subsidiary Jubilant Pharma Holdings Inc (JPHI) has entered in an agreement with Standard Chartered Bank for a five-year loan facility for repayment of existing term loan and bonds aggregating USD 350 million and additional tranche of USD 50 million for future growth capex," the company said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app